The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (TomudexTM) in a nonhuman primate model

[1]  S. Clarke,et al.  Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Seymour,et al.  ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Pazdur,et al.  'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Martin H. Kroll,et al.  MLAB: A Mathematical Modeling Laboratory. Civilized Software, Inc., Bethesda, MD, 1995. DOS version starts at $1495. Manuals included: MLAB Reference Manual by Barry Bunow and Gary Knott, MLAB Applications Manual by Gary Knott, and The Graphics Manual by Dan Kerner , 1995 .

[5]  A. Jackman,et al.  ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. , 1995, European journal of cancer.

[6]  L. Kèlland,et al.  Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. , 1995, British Journal of Cancer.

[7]  P. Adamson,et al.  Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey. , 1995, Cancer research.

[8]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[9]  F. Balis,et al.  A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. , 1990, Laboratory animal science.

[10]  S. Clarke,et al.  Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models. , 1998, British Journal of Cancer.

[11]  A. Jackman,et al.  The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. , 1993, Advances in experimental medicine and biology.

[12]  S. Clarke,et al.  The history of the development and clinical use of CB 3717 and ICI D1694. , 1993, Advances in experimental medicine and biology.